Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three active pharmaceutical ingredients: - **Sorbitol** is a sugar alcohol used primarily as an osmotic laxative to relieve constipation and as a pharmaceutical excipient. It works by drawing water into the large intestine, stimulating bowel movements[1]. - **Phenylephrine** is an alpha-1 adrenergic receptor agonist commonly used as a decongestant. It causes vasoconstriction, leading to reduced swelling and congestion in nasal passages. - **Morphine** is an opioid analgesic that acts mainly as an agonist at mu-opioid receptors in the central nervous system, blocking pain signal transmission and altering pain perception[2][3]. Morphine also has activity at kappa and delta opioid receptors. There are no widely recognized or approved pharmaceutical products combining all three agents (sorbitol, phenylephrine, and morphine) into one formulation. Each component has distinct indications—sorbitol for constipation or use as an excipient; phenylephrine for nasal congestion; morphine for moderate to severe pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sorbitol + phenylephrine + morphine.